Susan G. Komen for the Cure®, the world’s leading breast cancer organization, today launched a major new outreach to dramatically improve cancer screening, education and outreach in the Latina community, where breast cancer is the leading cause of cancer death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50756-susan-g-komen-for-the-cure-latina-community-improve-breast-cancer-outreach
Today in New York, Avon Foundation for Women Honorary Chairperson Reese Witherspoon recognized Breast Cancer Awareness Month at the 2011 Global Breast Cancer Congress – where she launched a new Avon Foundation for Women-funded global breast cancer scholarship program – and at the Avon Walk for Breast Cancer – where she presented more than $9.1 million in grants to New York-area breast cancer programs.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46209-reese-witherspoon-announces-avon-global-breast-cancer-scholars-program
Avon Products, Inc. celebrated the culmination of its 125th anniversary year last night at the Avon Foundation for Women Global Voices for Change Gala by honoring global champions working to end breast cancer and domestic violence, and by announcing the winners of Avon’s first-ever global online singing talent search for women and songwriting competition for women and men, Avon Voices. Avon Chairman and CEO Andrea Jung, Fergie, Natasha Bedingfield, Delta Goodrem, Ashley Greene and more than 800 guests and performers from 39 countries attended this star-studded celebration at the Marriot Marquis in New York City’s Times Square, which raised more than $2.3 million for the Avon Foundation for Women.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46211-avon-global-voices-for-change-gala
On November 17, millions of Americans will mark the American Cancer Society’s 36th annual Great American Smokeout by giving up smoking for the day, and maybe for good. Because smoking can trigger asthma symptoms in children, quitting is an important first step toward protecting kids’ health. BeSmartBeWell.com tells parents the steps they can take on the Great American Smokeout, and every day of the year, to lower the risk for childhood asthma.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/childhoodasthma/50826/
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
St. Jude Children’s Research Hospital is launching a new series of public service announcements (PSAs) to help raise awareness and deepen the understanding of the hospital’s lifesaving mission through real St. Jude heroes – its patients and families. St. Jude has not produced national PSAs since 2003 and timed this new multichannel campaign to coincide with the hospital’s 50th anniversary.
The PSAs share St. Jude moments through patients and families like 10-year-old Angiel. Angiel and her mom Damaris were planning a trip to Africa for a family reunion when she was diagnosed with osteosarcoma, a type of bone cancer that produced tumors in both of Angiel’s legs. Today, thanks to St. Jude doctors, Angiel can still look forward to visiting family in a foreign land one day. Angiel’s story is just one of several patients featured in the PSAs.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/stjude/46749/
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
At its annual meeting of more than 10,000 financial representatives and staff members today, Northwestern Mutual announced its new multi-year philanthropic program to fight childhood cancer. The effort, through the Northwestern Mutual Foundation, builds upon the company’s legacy of helping children and families. It leverages Northwestern Mutual’s field force throughout the country to implement a range of community events and programs to raise awareness and money for pediatric cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53645-northwestern-mutual-philanthropic-campaign-pediatric-cancer-research
The Oral Cancer Foundation is pleased to have developed partnerships with two highly visible Hollywood stars to raise awareness of a disease of which too few people in the U.S. have ever heard. Academy Award winning actor, Michael Douglas, who has recently completed successful treatment for an advanced oral cancer, and Emmy and Tony Award winning actress, Blythe Danner, who lost her husband to the same disease have partnered with OCF to send a very important message about screening and early detection of oral cancer to the American public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57170-oral-cancer-foundation-michael-douglas-early-detection-psa-campaign
